"10.1371_journal.pone.0139584","plos one","2015-10-01T00:00:00Z","Thandokuhle Khumalo; Eloise Ferreira; Katarina Jovanovic; Rob B Veale; Stefan F T Weiss","School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, The Republic of South Africa (RSA)","Conceived and designed the experiments: SFTW RBV. Performed the experiments: TK EF KJ. Analyzed the data: TK EF KJ. Wrote the paper: TK EF.","S.F.T.W. is currently a PLOS ONE Editorial Board Member. The patent, EP1670826, co-owned by the University of the Witwatersrand and Affimed Therapeutics AG covers LRP/LR specific antibodies used in this study as tools for diagnosis and therapy of cancer. This granted European patent was validated in the United Kingdom, France, Germany, Switzerland and Austria. Further, a South African Provisional Patent Application 2014/08860, owned by the University of the Witwatersrand covers the inhibition of the development of cancer cells by the modification of the levels of LRP/LR. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","10","Thandokuhle Khumalo","TK",5,TRUE,2,3,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
